SERUM IMMUNOSUPPRESSIVE ACIDIC PROTEIN AND NATURAL KILLER CELL ACTIVITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA BEFORE AND AFTER NEPHRECTOMY
- 1 September 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 164 (3 Part 1) , 673-675
- https://doi.org/10.1016/s0022-5347(05)67278-3
Abstract
Conclusions Our study implies that nephrectomy may be beneficial in patients with elevated serum C-reactive protein before treatment. Further evaluation by a prospective study is needed to make a definitive conclusion.Keywords
This publication has 14 references indexed in Scilit:
- SERUM C-REACTIVE PROTEIN LEVEL AND THE IMPACT OF CYTOREDUCTIVE SURGERY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMAJournal of Urology, 1999
- Kidney cancerThe Lancet, 1998
- Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 1998
- CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMAJournal of Urology, 1997
- Cytoreductive Surgery for Stage IV Renal Cell CarcinomaJournal of Urology, 1995
- Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response ModifiersJournal of Urology, 1995
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.Journal of Clinical Oncology, 1995
- Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.Journal of Clinical Oncology, 1993
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985